Replies to post #44380 on PharmaCyte Biotech Inc (PMCB)

[BioNewton]

Gee I wonder if the relationship would end during clinical trials. Oh, of course not. Austrianova needs PMCB.

[BioNewton]

You are not saying anything that everyone doesn't already know! Of course they can't market a treatment until it's approved no one is saying they can. People are merely pointing out what the orphan drug designation provides and that is seven years of marketing exclusivity in the US and 10 years of marketing exclusivity in Europe. With regard to the patents, you clearly don't know how patent protection works. A company doesn't extend its patents until one month prior to expiration.

Pharmacyte has a patent attorney already in place, so that likely means that they have a patent protection strategy in place. In case you were not aware, the CEO is an attorney and has worked with very large companies in the past so this isn't his first rodeo and the patent attorney that they're working with this is likely not his first rodeo. Some may hope that the company's patents will run out, but that is highly unlikely to happen because they are not just sitting around eating bonbons clueless as to how to protect their treatment and technology!!! You don't extend your patents until the last possible date obviously because you want as much time on the new patent as possible!

[BioNewton]

Pharmacyte will easily get patent extensions, so all the wishful thinking in the world won't stop the inevitable! Now just for the sake of argument, I will indulge those who hope Pharmacyte does not get patent extensions. If they do not get patent extensions (which they will), it would take another company or entity 7-plus years to figure out how to duplicate the treatment. Cell in a Box and the genetically modified cells inside are not a tablet that can easily be reverse engineered.

The entity would first have to figure out which type of cotton is used (there are many cottons and according to Dr. Gunzburg only one type will work) and then make the specific modifications to that one specific type of cotton that allows it to work, then they'd have to create the machines that make the process work, and then they would have to figure out how to genetically modify the cells, and then they would have to figure out the cell growing process to get just the right amount per capsule, and then they'd have to wait for the freezing patent to run out so they could then figure out how this particular product can be frozen so it doesn't have to be used immediately upon production and so they could ship it, and then they'd have to figure out the right placement of the capsules, and the right amount of ifosfamide to use, etc. etc. etc. etc.

Then if they figure all of that out, they'd have to take their newly created product through preclinical studies and clinical trials... And by that time, Pharmacyte would have had FDA approval for a long time and they'd be using the 7 years of marketing exclusivity that the orphan drug status provides.